This trial is active, not recruiting.

Condition abdominal fat
Treatments high intensity focused ultrasound device, noninvasive cryolipolysis device
Sponsor Northwestern University
Start date October 2013
End date December 2017
Trial size 15 participants
Trial identifier NCT01976247, STU84032


The purpose of this study is to compare the safety and effectiveness of the Zeltiq System and LipoSonix System for fat reduction and improving body shape.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking single blind (outcomes assessor)
(Active Comparator)
The Zeltiq System is a noninvasive (not breaking the skin) device that reduces fat by freezing fat cells until they break apart.
noninvasive cryolipolysis device Zeltiq
(Active Comparator)
The LipoSonix System is a noninvasive ultrasound device, which can be used to selectively target and destroy fat tissue located deep under the skin.
high intensity focused ultrasound device Liposonix

Primary Outcomes

Change in best overall cosmetic appearance (right side or left side better)rated by a blinded dermatologist from baseline to week 12
time frame: 1 hour at baseline and week 12

Eligibility Criteria

Female participants from 30 years up to 65 years old.

Inclusion Criteria: 1. Female subjects ages 30-65 years old. 2. Body mass index (BMI) between 18 and 29.99. (BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches). 3. Subjects are in good health. 4. Willing and able to abstain from partaking in any treatment other than the study procedure (existing or new) to promote body contouring and/or weight loss during the course of study participation. 5. Subjects agree to maintain their weight (i.e. within 5 pounds) by not making any changes to diet or lifestyle during the study. 6. The subjects have the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator. Exclusion Criteria: 1. Pregnant or lactating or intends to become pregnant in the next 9 months. 2. Unable to understand the protocol or to give informed consent. 3. Any previous and/or pending procedures at the treatment area or that may likely affect the treatment area. 4. Pending and/or anticipated major change in diet or exercise pattern in the six weeks following the last treatment or who has taken diet pills within the last 6 months.. 5. History of asthma or chronic obstructive pulmonary diseases. 6. Active skin disease or skin infection in the treatment area. 7. Bleeding tendency or coagulopathy. 8. Subjects who are allergic to lidocaine. 9. Any other condition that would, in the professional opinion of the investigator, potentially affect response or participation in the clinical study, or would pose as an unacceptable risk to the subject.

Additional Information

Official title Pilot Study Comparing the Effectiveness of a Noninvasive Cryolipolysis Device vs. a High Intensity Focused Ultrasound Device for Fat Reduction: A Randomized Control Trial
Principal investigator Murad Alam, MD
Description At baseline visit, subjects who meet inclusion and exclusion criteria will be enrolled. Subjects will be randomly assigned to receive Zeltiq treatment to either their right or left flank The contralateral flank will receive Liposonix treatment. A total of three identical treatments will be completed monthly for 3 consecutive months. Subjects will return 4 weeks following the last treatment for follow up photography, measurements, and assessments. This study is a pilot study designed to determine feasibility of these procedures.
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by Northwestern University.